Skip to main content

Advertisement

SpringerLink
Log in

Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus

  • Original Article
  • Published:
Clinical Rheumatology Aims and scope Submit manuscript

Abstract

Antinucleosome antibodies (AnuA) are increasingly recognized as an important biomarker in the diagnosis and subset stratification of patients with systemic lupus erythematosus (SLE). The aim of the study was to determine the sensitivity, specificity, and clinico-serological correlates of AnuA in black South Africans with SLE. We performed a cross-sectional study of 86 SLE patients attending a tertiary center and 87 control subjects. AnuA were tested using a second-generation enzyme-linked immunosorbent assay (ELISA). The sensitivity, specificity, positive predictive value, and negative predictive value of AnuA were 45.3, 94.3, 88.6, and 63.6%, respectively. The presence of AnuA were strongly associated with the co-presence of anti-dsDNA antibodies (OR = 3.4, p < 0.0005) and antihistone antibodies (OR = 15.7, p < 0.00001). Patients who were seropositive for AnuA were more likely to have skin involvement (discoid lupus and/or malar rash) and had higher SLE disease activity index (SLEDAI) scores and Systemic Lupus International Collaborative Clinics/American College of Rheumatology (SLICC/ACR) damage scores (p < 0.05). IgG anticardiolipin antibody (aCL) levels showed a significant correlation with AnuA ratios (p < 0.01). Our findings provide further evidence that AnuA are a sensitive and specific diagnostic biomarker in SLE. Moreover, our finding that the presence of AnuA, but not anti-dsDNA antibodies, are associated with worse SLICC/ACR damage scores suggest that AnuA may have a role in predicting disease outcome. The correlation between IgG aCL and AnuA is a novel finding that merits further studies to determine possible common peptide specificities of the antibodies.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1

Similar content being viewed by others

References

  1. Koutouzov S, Jeronimo AL, Campos H, Amoura Z (2004) Nucleosomes in the pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 30:529–558

    Article  PubMed  Google Scholar 

  2. Amoura Z, Koutouzov S, Piette JC (2000) The role of nucleosomes in lupus. Curr Opin Rheumatol 12:369–373

    Article  CAS  PubMed  Google Scholar 

  3. Bruns A, Blass S, Hausdorf G, Burmester GR, Hiepe F (2000) Nucleosomes are major T and B cell autoantigens in systemic lupus erythematosus. Arthritis Rheum 43:2307–2315

    Article  CAS  PubMed  Google Scholar 

  4. Cervera R, Vinas O, Ramos-Casals M et al (2003) Anti-chromatin antibodies in systemic lupus erythematosus: a useful marker for lupus nephropathy. Ann Rheum Dis 62:431–434

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Saisoong S, Eiam-Ong S, Hanvivatvong O (2006) Correlations between antinucleosome antibodies and anti-double-stranded DNA antibodies, C3, C4, and clinical activity in lupus patients. Clin Exp Rheumatol 24:51–58

    CAS  PubMed  Google Scholar 

  6. Benucci M, Gobbi FL, Del Rosso A, Cesaretti S, Niccoli L, Cantini F (2003) Disease activity and antinucleosome antibodies in systemic lupus erythematosus. Scand J Rheumatol 32:42–45

    Article  PubMed  Google Scholar 

  7. Tikly M, Burgin S, Mohanlal P, Bellingan A, George J (1996) Autoantibodies in black South Africans with systemic lupus erythematosus: spectrum and clinical associations. Clin Rheumatol 15:261–265

    Article  CAS  PubMed  Google Scholar 

  8. Petri M (2005) Review of classification criteria for systemic lupus erythematosus. Rheum Dis Clin North Am 31:245–254

    Article  PubMed  Google Scholar 

  9. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725

    Article  CAS  PubMed  Google Scholar 

  10. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH (1992) Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 35:630–640

    Article  CAS  PubMed  Google Scholar 

  11. Gladman D, Ginzler E, Goldsmith C et al (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369

    Article  CAS  PubMed  Google Scholar 

  12. Loizou S, Singh S, Wypkema E, Asherson RA (2003) Anticardiolipin, anti-beta(2)-glycoprotein I and antiprothrombin antibodies in black South African patients with infectious disease. Ann Rheum Dis 62:1106–1111

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Statistica for Windows. 5.1 ed. Statsoft 1998, Tulsa

  14. Min DJ, Kim SH, Park SH et al (2002) Anti-nucleosome antibody: significance in lupus patients lacking anti-double stranded DNA antibody. Clin Exp Rheumatol 20:13–18

    CAS  PubMed  Google Scholar 

  15. Haddouk S, Ben Ayed M, Baklouti S, Hachicha J, Bahloul Z, Masmoudi H (2005) Clinical significance of antinucleosome antibodies in Tunisian systemic lupus erythematosus patients. Clin Rheumatol 24:219–222

    Article  CAS  PubMed  Google Scholar 

  16. Villalta D, Tozzoli R, Bizzaro N, Tonutti E, Ghirardello A, Doria A (2005) The relevance of autoantigen source and cutoff definition in antichromatin (nucleosome) antibody immunoassays. Ann N Y Acad Sci 1050:176–184

    Article  CAS  PubMed  Google Scholar 

  17. Amoura Z, Koutouzov S, Chabre H et al (2000) Presence of anti-nucleosome antibodies in a restricted set of connective tissue diseases: antinucleosome antibodies of the IgG3 subclass are markers of renal pathogenicity in systemic lupus erythematosus. Arthritis Rheum 43:76–84

    Article  CAS  PubMed  Google Scholar 

  18. Sallai K, Nagy E, Derfalvy B, Muzes G, Gergely P (2005) Antinucleosome antibodies and decreased deoxyribonuclease activity in sera of patients with systemic lupus erythematosus. Clin Diagn Lab Immunol 12:56–59

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Cairns AP, McMillan SA, Crockard AD et al (2003) Antinucleosome antibodies in the diagnosis of systemic lupus erythematosus. Ann Rheum Dis 62:272–273

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Ghirardello A, Doria A, Zampieri S et al (2004) Antinucleosome antibodies in SLE: a two-year follow-up study of 101 patients. J Autoimmun 22:235–240

    Article  CAS  PubMed  Google Scholar 

  21. Horak P, Scudla V, Hermanovo Z et al (2001) Clinical utility of selected disease activity markers in patients with systemic lupus erythematosus. Clin Rheumatol 20:337–344

    Article  CAS  PubMed  Google Scholar 

  22. Su Y, Jia RL, Han L, Li ZG (2007) Role of anti-nucleosome antibody in the diagnosis of systemic lupus erythematosus. Clin Immunol 122:115–120

    Article  CAS  PubMed  Google Scholar 

  23. Simon JA, Cabiedes J, Ortiz E, Alcocer-Varela J, Sanchez-Guerrero J (2004) Anti-nucleosome antibodies in patients with systemic lupus erythematosus of recent onset. Potential utility as a diagnostic tool and disease activity marker. Rheumatol (Oxf) 43:220–224

    Article  CAS  Google Scholar 

  24. Grootscholten C, van Bruggen MC, van der Pijl JW et al (2003) Deposition of nucleosomal antigens (histones and DNA) in the epidermal basement membrane in human lupus nephritis. Arthritis Rheum 48:1355–1362

    Article  CAS  PubMed  Google Scholar 

  25. Smeenk RJ, Lucassen WA, Swaak TJ (1987) Is anticardiolipin activity a cross-reaction of anti-dsDNA or a separate entity? Arthritis Rheum 30:607–617

    Article  CAS  PubMed  Google Scholar 

  26. Sharma A, Isenberg D, Diamond B (2003) Studies of human polyclonal and monoclonal antibodies binding to lupus autoantigens and cross-recative antigens. Rheumatology 42:453–460

    Article  CAS  PubMed  Google Scholar 

  27. Abraham Simon J, Rojas-Serrano J, Cabiedes J, Alcocer-Varelo J (2004) Antinucleosome antibodies may help to predict development of systemic lupus erythematosus in patients with primary antiphospholipid syndrome. Lupus 13:177–181

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We would like to thank Dr. Neil McHugh for his thoughtful suggestions.

Author information

Authors and Affiliations

  1. Division of Rheumatology, Department of Medicine, Chris Hani Baragwanath Hospital and University of the Witwatersrand, P.O. Bertsham 2013, Johannesburg, South Africa

    M. Tikly & T. Gould

  2. Department of Immunology, National Health Laboratory Services and University of the Witwatersrand, Johannesburg, South Africa

    A. A. Wadee, E. van der Westhuizen & B. B. N. Mokgethwa

Authors
  1. M. Tikly
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. T. Gould
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. A. Wadee
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. van der Westhuizen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. B. B. N. Mokgethwa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Tikly.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tikly, M., Gould, T., Wadee, A.A. et al. Clinical and serological correlates of antinucleosome antibodies in South Africans with systemic lupus erythematosus. Clin Rheumatol 26, 2121–2125 (2007). https://doi.org/10.1007/s10067-007-0637-7

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10067-007-0637-7

Keywords

Search

Navigation